EP08.02-004 Aumolertinib in Treatment-Naïve EGFR-mutant NSCLC Patients With Brain Metastases: Primary Efficacy and Safety Data from the ARTISTRY

Abstract

Listen

Translate article

ARTISTRY (NCT04778800) is an ongoing dose-escalation study evaluating third-generation EGFR-TKI aumolertinib (formerly almonertinib; HS-10296) in three cohorts of EGFR-mutant NSCLC patients with brain/leptomeningeal metastases. The study design was previously presented at ESMO 2021. Here we report primary efficacy and safety data of the brain parenchyma metastases cohort from the ARTISTRY.